IP Library Granted Patent US 9,682,055
Granted Patent B2
US 9,682,055 · App. 14/730,818 · Granted Jun 20, 2017

Pharmaceutical compositions comprising DGLA and use of same

Inventors: Mehar Manku (Birmingham, GB); John Climax (Dublin, IE); David Coughlan (Dublin, IE); James Dunne (Dublin, IE)
Assignee: DIGNITY SCIENCES LIMTED
A61K31/202A61K8/11A61K8/361A61K8/65A61K9/0053A61K9/48A61K9/4825A61Q19/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,682,055
App. No.
14/730,818
Granted
Jun 20, 2017
Kind
B2
Abstract

The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.

Claims (6)

1. A pharmaceutical composition comprising dihomo gamma linolenic acid, eicosatetraenoic acid, eicosatrienoic acid, oleic acid, linoleic acid and eicosadienoic acid encapsulated in a capsule shell wherein the composition comprises at least about 80% dihomo gamma linolenic acid by weight of total fatty acids.

2. The pharmaceutical composition of claim 1 , wherein the capsule shell comprises gelatin and glycerol.

3. The pharmaceutical composition of claim 1 , wherein up to about 1 g of dihomo gamma linolenic acid is encapsulated in the capsule shell.

4. The pharmaceutical composition of claim 1 , wherein about 200 mg to about 1 g of dihomo gamma linolenic acid is encapsulated in the capsule shell.

5. The pharmaceutical composition of claim 1 , wherein the capsule shell comprises lime bone gelatin and the capsule shell further comprises one or more of: glycerol, purified water, titanium dioxide, medium chain triglycerides and/or lecithin.

6. The pharmaceutical composition of claim 1 , comprising about 200 mg to about 1 g of dihomo gamma linolenic acid and wherein the composition comprises not more than 5% of any individual fatty acid other than dihomo gamma linolenic acid by weight of total fatty acids.

Assignments (3)
CHANGE OF NAME Recorded Jul 31, 2017
From: DIGNITY SCIENCES LIMITED
To: DS BIOPHARMA LIMITED
Reel/Frame 043147/0143 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2016
From: MANKU, MEHAR; CLIMAX, JOHN; COUGHLAN, DAVID; DUNNE, JAMES
To: DIGNITY SCIENCES LIMITED
Reel/Frame 040279/0912 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2015
From: MANKU, MEHAR; CLIMAX, JOHN; COUGHLAN, DAVID; DUNNE, JAMES
To: DIGNITY SCIENCES LIMITED
Reel/Frame 035788/0889 →
Continuity (3)
Provisional Application 62058469 · Oct 1, 2014
Provisional Application 62007752 · Jun 4, 2014
Related Publication 20150352053A1 · Dec 10, 2015